The More Densely Antigens Are Arranged, the Longer Immune Memory Lasts: Nanovaccine Studies Identify a Design Clue for Prolonging B-Cell Responses

Vaccines must not only enable the immune system to “see” an antigen, but also ensure that the resulting memory lasts long enough. Two preclinical studies conducted through a collaboration among Scripps Research, the University of Texas Medical Branch, and the International AIDS Vaccine Initiative found that arranging antigens in a highly repetitive pattern on the surface of nanoparticles can give specific B cells a more sustained survival and maturation advantage, offering a structural design principle for HIV vaccines, for which establishing long-term protection has been difficult.

The research team focused on avidity, the overall binding strength formed when a nanoparticle binds to B-cell receptors through multiple points of contact. It depends on both the number of recognizable antigens on the particle’s surface and the single-site affinity of each contact point. In the past, these two factors often varied together, making it difficult to determine which was more important. In this research, the investigators produced six types of nanoparticles with similar size and other characteristics but with between zero and 60 functional binding sites, allowing them to separate the effects of the two factors.

Mouse vaccination experiments showed that the more densely functional antigens were arranged, the longer germinal center responses were sustained, and the stronger the generation and persistence of memory B cells, long-lived plasma cells, and circulating antibodies. The research team also used control experiments to rule out the explanation that the effect resulted simply from administering more antigen. The results support the conclusion that the key lies in the repetitive arrangement on the same particle, rather than in the total amount of antigen itself.

A companion study further tracked competition within germinal centers. These are important sites where activated B cells are selected, proliferate, and mature. Precursor B cells that could capture highly repetitive nanoparticles more effectively were more likely to persist and expand during competition. Increasing single-site affinity was also helpful, but its effect was less pronounced than that of multivalent arrangement. B-cell receptor sequencing also showed that antigen valency had limited effects on individual somatic mutations, but increased the clonal diversity participating in the response.

This difference was evident only when B cells competed with one another. When the researchers reduced the number of other precursor B cells, the gap between nanoparticles with low and high valency disappeared. This provides one possible explanation: some vaccines with sparsely arranged antigens may perform well in animal models with simplified immune compositions, yet after entering the human body, which has diverse B-cell populations, the target cells may not necessarily prevail in the competition.

The current evidence remains limited to specially engineered mouse models carrying specific precursor B cells, and the research did not demonstrate that this type of nanovaccine can prevent HIV infection in humans. Whether antigen density can similarly prolong protection in more natural immune environments, nonhuman primates, and clinical trials remains to be verified. Nevertheless, the research elevates “how antigens are arranged” from a formulation detail to a quantifiable design variable and may also provide a direction for investigating vaccines against other infectious diseases that require durable antibody responses.